Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)

The summary for the Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this FOA, the term complex can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms, these are neither required nor expected. Studies should not attempt to model disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic target identification. The present announcement seeks R21 applications for high risk or early stage exploratory research.

Federal Grant Title:	Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-20-264
Type of Funding:	Grant
CFDA Numbers:	93.242
CFDA Descriptions:	Information not provided
Current Application Deadline:	September 7th, 2023
Original Application Deadline:	September 7th, 2023
Posted Date:	August 10th, 2020
Creation Date:	August 10th, 2020
Archive Date:	October 13th, 2023
Total Program Funding:
Maximum Federal Grant Award:	$200,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	August 10th, 2020

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PAR-20-264.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH...; • Interaction between ARVs and Hormones in HIV and Coinfections (R01 Clinical Trial Optional...; • Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowe...; • Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...; • Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...; • Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...; • Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...